Should I buy Teva Pharmaceuticals stock in 2025?
Is Teva Pharmaceuticals stock a buy right now?
ScoreAs of late May 2025, Teva Pharmaceuticals (NYSE: TEVA) is trading at approximately $17.53 per share, with an average daily trading volume of 12.3 million shares, reflecting ongoing active investor engagement. While the stock has shown some volatility year-to-date (-20.46%), it has sustained a steady recovery over the past 6 to 12 months, aligning with broader sector trends in pharmaceuticals. Teva, a global leader in generic and specialty medicines, recently posted its ninth consecutive quarter of revenue growth, driven by standout performances from AUSTEDO and UZEDY, both surpassing forecasts in 2024. The pipeline remains robust, highlighted by key milestones such as FDA fast track designation for TEV-53408 in coeliac disease and successful progression of the anti-TL1A candidate Duvakitug. Market sentiment is constructively neutral, with technical indicators (MACD, Moving Averages) showing a slight positive bias. Notably, the consensus target price from over 33 national and international banks currently stands at $22.79, indicating broad confidence in the company's ongoing transformation and growth strategy. Within the pharmaceutical sector, Teva's innovation in biosimilars and continued adaptation make it an interesting candidate for careful consideration in a diversified portfolio.
- ✅Sustained revenue growth for nine consecutive quarters under new strategic direction.
- ✅Strong performance of flagship products AUSTEDO and UZEDY, both exceeding 2024 expectations.
- ✅Expanding biosimilars pipeline with 18 assets, enhancing long-term innovation prospects.
- ✅Successful cost management, with free cash flow of $2.07 billion in 2024.
- ✅Global industry leader in generics with a presence in 57 markets.
- ❌High debt burden remains, though showing continued improvement in recent quarters.
- ❌Meaningful exposure to geopolitical risks in Israel, managed proactively by management.
Score- ✅Sustained revenue growth for nine consecutive quarters under new strategic direction.
- ✅Strong performance of flagship products AUSTEDO and UZEDY, both exceeding 2024 expectations.
- ✅Expanding biosimilars pipeline with 18 assets, enhancing long-term innovation prospects.
- ✅Successful cost management, with free cash flow of $2.07 billion in 2024.
- ✅Global industry leader in generics with a presence in 57 markets.
Is Teva Pharmaceuticals stock a buy right now?
- ✅Sustained revenue growth for nine consecutive quarters under new strategic direction.
- ✅Strong performance of flagship products AUSTEDO and UZEDY, both exceeding 2024 expectations.
- ✅Expanding biosimilars pipeline with 18 assets, enhancing long-term innovation prospects.
- ✅Successful cost management, with free cash flow of $2.07 billion in 2024.
- ✅Global industry leader in generics with a presence in 57 markets.
- ❌High debt burden remains, though showing continued improvement in recent quarters.
- ❌Meaningful exposure to geopolitical risks in Israel, managed proactively by management.
Score- ✅Sustained revenue growth for nine consecutive quarters under new strategic direction.
- ✅Strong performance of flagship products AUSTEDO and UZEDY, both exceeding 2024 expectations.
- ✅Expanding biosimilars pipeline with 18 assets, enhancing long-term innovation prospects.
- ✅Successful cost management, with free cash flow of $2.07 billion in 2024.
- ✅Global industry leader in generics with a presence in 57 markets.
- What is Teva Pharmaceuticals?
- How much is the Teva Pharmaceuticals stock?
- Our full analysis on Teva Pharmaceuticals stock
- How to buy Teva Pharmaceuticals stock in Ireland?
- Our 7 tips for buying Teva Pharmaceuticals stock
- The latest news about Teva Pharmaceuticals
- FAQ
What is Teva Pharmaceuticals?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | Israel | Company based in Israel, offering strong presence across 57 international markets. |
| 💼 Market | NYSE (New York Stock Exchange) | Listed on NYSE, providing good liquidity and access for global investors, including those in IE. |
| 🏛️ ISIN code | US8816242098 | US ISIN for ADRs allows straightforward trading via international brokerage accounts. |
| 👤 CEO | Richard Francis | Driving the “Pivot to Growth” strategy, showing operational turnaround and consistent performance. |
| 🏢 Market cap | $20.35 billion | Large-cap status reflects strong scale and steady investor interest. |
| 📈 Revenue | $16.54 billion (2024); $16.8–$17.4B expected (2025) | Revenue growing steadily, with forecasts showing further expansion in 2025. |
| 💹 EBITDA | $4.78 billion (2024); $4.5–$5.0B expected (2025) | Robust EBITDA provides operating flexibility and supports continued investment in innovation. |
| 📊 P/E Ratio (Price/Earnings) | N/A (negative; losses on GAAP basis) | No P/E due to negative earnings, but strong non-GAAP profits and improving trend are positives. |
How much is the Teva Pharmaceuticals stock?
The price of Teva Pharmaceuticals stock is declining this week. As of now, TEVA shares are trading at $17.53, marking a 3.42% drop over the past 24 hours and a 3.36% decrease across the week. The company's market capitalisation stands at $20.35 billion, with a 3-month average daily volume of 12.3 million shares. The price/earnings (P/E) ratio is currently not applicable due to recent losses, and no dividend yield is offered. TEVA’s beta is 0.63, suggesting relatively low volatility compared to the wider market—an aspect that may appeal to cautious investors monitoring stability within the pharmaceutical sector.
Compare the finest brokers in Ireland and find the best one for you!Compare brokersOur full analysis on Teva Pharmaceuticals stock
Having closely analysed Teva Pharmaceuticals' (NYSE: TEVA) latest quarterly and annual results, as well as its share price evolution over the last three years, we have leveraged a suite of data-driven approaches encompassing financial ratios, proprietary technical signals, real-time market dynamics, and detailed peer benchmarking. Synthesising these insights through our advanced algorithms, we arrive at a crucial consideration for 2025: why might Teva Pharmaceuticals stock once again become a strategic entry point into the ever-evolving global healthcare and biotechnology sector?
Recent Performance and Market Context
Teva has displayed resilient stock behaviour despite episodic intraday volatility, currently trading at $17.53 (as of May 30th, 2025). Over the past 52 weeks, TEVA shares have oscillated between $12.47 and $22.80, revealing sizeable upside potential from the current price, especially given the consensus analyst target of $23.12. After a modest 6.57% gain over the past year and a 4.47% rise in the last six months, the stock nevertheless finds itself down 20.46% year-to-date—an apparent lag that, on closer analysis, highlights a possible opportunity amid sector rotation and investor repositioning.
Crucially, Teva reported its ninth consecutive quarter of revenue growth through Q1 2025. The health of its innovative product portfolio, especially the outperformance of treatments like AUSTEDO ($1.6bn revenue in 2024, ahead of expectations) and UZEDY ($117m in 2024 versus a $100m target), has provided a robust fundamental platform. Meanwhile, the pharmaceutical sector continues to enjoy a favourable macro backdrop, with global demand for generic and specialty medications on the rise amid regulatory tailwinds in the US and EU. For IE investors, exposure to global players like Teva offers appealing diversification in both currency and market dynamics.
Technical Analysis
Teva’s technical landscape is currently neutral with an emerging bullish tilt. The 14-day Relative Strength Index (RSI) stands at 49.05—firmly neutral but close to levels where upward momentum often builds. The MACD (+0.09) flashes a buy signal, indicating a favourable shift in price momentum, while the Stochastic (9,6) at 17.37 places the stock in oversold territory—suggesting that downside risk is becoming increasingly limited.
- 5-day MA: $17.49 (buy signal)
- 50-day MA: $17.20 (buy signal)
- 100-day MA: $17.22 (buy signal)
- 200-day MA: $16.28 (buy signal)
The most prominent technical support is identified at $17.34 (near today's low), while resistance stands at $18.28 (today's high). This compact trading range highlights a consolidation phase, typically the precursor to renewed strength if catalysts unfold.
Overall, technical indicators reinforce the notion that Teva may be entering a new bullish phase, and that the share is well-supported for accumulation near recent lows.
Fundamental Analysis
Teva’s transformation over the past two years is underpinned by operational excellence and strategic vision. Annual revenue for 2024 reached $16.54bn (+6% in local currencies), and adjusted EBITDA climbed to $4.78bn. Notably, Q4 free cash flow was $790m, and full-year free cash flow hit $2.07bn, indicating strong underlying performance.
While trailing earnings (TTM EPS: -$1.15) remain negative due to legacy challenges, the company’s non-GAAP EPS for 2024 stood at an impressive $2.49—comfortably beating expectations and demonstrating the underlying health of core operations. The lack of a current dividend redistributes resources towards R&D and debt reduction, both prudent at this phase of Teva's evolution.
| Market Capitalisation | $20.35bn |
|---|---|
| Historic sector multiples | Forward-looking valuation is compelling despite negative trailing P/E |
| PEG Ratio | Not available due to negative earnings, but robust EBITDA and sales multiples |
Teva’s structural strengths should not be underestimated:
- Innovation pipeline: 18 biosimilar assets in development.
- Market share: Leadership in generics across the US and Europe.
- Brand: Recognised as a trusted supplier to healthcare systems globally.
- Management: Strategic “Pivot to Growth” is reaffirmed each quarter, under CEO Richard Francis.
Volume and Liquidity
Teva is consistently one of the most actively traded pharmaceutical stocks on the NYSE, with a 3-month average daily trading volume of 12.3 million shares. This high liquidity provides a dynamic environment for both retail and institutional investors, translating to orderly price discovery and tight bid-ask spreads. The outstanding float (1.15bn shares) supports a market that can absorb significant inflows without distorting valuation, and also allows for relatively efficient portfolio rebalancing—an appealing characteristic for active investors in IE seeking overseas equities.
Catalysts and Positive Outlook
- Product Innovation: AUSTEDO and UZEDY are rapidly becoming blockbuster anchors.
- Pipeline Expansion: The expected launch of SELARSDI and positive FDA ‘Fast Track’ designation for TEV-53408 (celiac disease) are set to drive news flow.
- Clinical Milestones: Duvakitug (anti-TL1A) is moving into pivotal Phase 3 trials in 2025 after promising Phase 2B results.
- Biosimilars: With 18 assets progressing, Teva is well-placed to address the vast “patent cliff” opportunity as leading biologics go off-patent.
- Operational Momentum: Nine consecutive quarters of growth, ongoing deleveraging (total debt falling from elevated levels), and improved free cash generation.
The sector context also remains constructive. Global health expenditure continues to trend higher, and innovation in specialty generics and biosimilars remains a coveted growth avenue—particularly as payors and health services worldwide seek cost containment and improved outcomes.
Investment Strategies
Teva’s risk-reward balance appears increasingly favourable across investment horizons:
- Short-Term Entry
- Recent pullback to strong technical support at $17.34
- Oversold short-term indicators and impending catalyst events (product launches, regulatory decisions)
- Attractive swing trade potential as price compresses towards the lower end of the 2025 analyst target range
- Medium-Term Positioning
- Building a position ahead of major pipeline announcements (SELARSDI launch, Duvakitug Phase 3)
- Outlook for sustained EBITDA and free cash margin expansion
- Potential for positive earnings surprises as analyst estimates remain conservative
- Re-rating opportunity as sector sentiment rotates back into undervalued growth names
- Long-Term Strategy
- Exposure to secular innovation in global healthcare, with a deeply diversified product base and geographic reach (57 markets, ~37,000 employees)
- Leadership in generics and biosimilars, well-suited for multiyear growth as demographic and regulatory trends remain supportive
- Consistent deleveraging and operational discipline increase resilience and optionality for value creation
For investors seeking a portfolio anchor in global pharma, accumulation near the current technical floor could be prudent ahead of a possible multi-quarter recovery.
Is it the Right Time to Buy Teva Pharmaceuticals?
Synthesising the analysis, Teva Pharmaceuticals emerges as a company decisively transitioning from a legacy turnaround story to a pioneering global player with clear leadership in generics, specialty pharmaceuticals, and biosimilars. The recent string of outperformance, robust pipeline maturation, and strategic focus under CEO Richard Francis are fundamentally altering the risk/reward proposition.
- Multiple consecutive quarters of earnings outperformance and revenue growth
- Significant new product catalysts (AUSTEDO, UZEDY, SELARSDI, Duvakitug)
- Expanding biosimilars and innovation pipelines
- Strong liquidity, institutional ownership, and high trading volume
- Valuation that remains attractive relative to peers despite visible growth momentum
While investors should remain mindful of moderate risks such as the company’s leverage (albeit on a downward trajectory) and its geopolitical exposure, these appear well-priced into the market. Analyst consensus is converging towards a more constructive stance, and recent upgrades reflect an emerging appreciation for Teva’s compelling growth profile.
In conclusion, Teva Pharmaceuticals seems to represent an excellent opportunity for investors looking to gain exposure to the convergence of healthcare innovation and global market diversification. With fundamentals and technicals aligning favourably and a pipeline brimming with near-term and long-term catalysts, Teva may be entering a fresh bullish phase that merits careful consideration as part of a diversified portfolio. For those seeking quality at a cyclical low, the current environment provides a strategic window to participate in the company’s renewed ascent.
How to buy Teva Pharmaceuticals stock in Ireland?
Buying shares in Teva Pharmaceuticals (ticker: TEVA), a leading global pharmaceutical company, is now simple and secure for Irish investors thanks to regulated online brokers. You can invest by purchasing actual Teva shares (“spot buying”) or trading using Contracts for Difference (CFDs), each offering distinct benefits. Spot buying means you own the shares directly, suitable for long-term investors, while CFDs allow you to speculate on price movements with leverage—ideal for short-term strategies. Below, we detail these two main approaches, with a useful broker comparison further down this page.
Spot Buying
A cash or spot purchase of Teva Pharmaceuticals stock means you buy real TEVA shares on the New York Stock Exchange, becoming a shareholder with voting rights and potential for capital gains. Most Irish-friendly brokers charge a fixed commission per order—typically between $4 and $10 (or the euro equivalent), often around $5 for modest amounts.
Example
Suppose the Teva share price is $17.53. With a $1,000 investment and a $5 brokerage fee, you could buy approximately 56 shares ($1,000 - $5 = $995; $995 ÷ $17.53 ≈ 56 shares).
Gain scenario: If the share price rises by 10%, your holding is now worth about $1,100 (56 × [$17.53 × 1.10]). Result: +$100 gross gain, or +10% on your initial investment (excluding taxes and currency conversion if applicable).
Trading via CFD
CFD trading allows you to speculate on the price changes of Teva Pharmaceuticals without owning the actual shares. CFDs typically require a lower capital outlay and offer leverage (often up to 5:1 for EU investors), amplifying both potential gains and risks. The main fees are the spread (the difference between buy and sell price) and overnight financing if you hold positions beyond a single day.
Example
You open a CFD position on Teva shares with $1,000 using 5x leverage, giving you market exposure of $5,000.
Gain scenario: If Teva’s price rises by 8%, your leveraged position grows by 8% × 5 = 40%. On your $1,000 initial margin, that’s a $400 gross gain (before subtracting spread and any overnight financing fees).
Final Advice
Before investing, carefully compare brokers’ fees, account types, and regulatory safeguards—these can impact both your costs and security as an Irish investor. Your chosen method will depend on your goals: spot buying suits long-term wealth building, while CFDs are aimed at experienced investors seeking short-term opportunities. A detailed broker comparison is available further down this page to help you make an informed, confident choice.
Compare the finest brokers in Ireland and find the best one for you!Compare brokersOur 7 tips for buying Teva Pharmaceuticals stock
| 📊 Step | 📝 Specific tip for Teva Pharmaceuticals |
|---|---|
| Analyse the market | Examine Teva’s recent 9 consecutive quarters of growth and its leadership in generics and biosimilars, highlighting resilient performance and positive outlook for 2025. |
| Choose the right trading platform | Opt for an Irish or EU-regulated broker that provides access to NYSE for purchasing TEVA shares in USD, ensuring compliance and low transaction fees. |
| Define your investment budget | Consider Teva’s moderate volatility and set an investment amount you are comfortable with, mindful of your wider portfolio and the absence of dividends. |
| Choose a strategy (short or long term) | A long-term approach suits Teva, given its continuous transformation, strong pipeline in biosimilars, and the company’s focus on sustainable growth. |
| Monitor news and financial results | Keep up to date with Teva’s quarterly earnings, product pipeline updates like AUSTEDO and UZEDY, and regulatory news that can quickly impact share price. |
| Use risk management tools | Place stop-loss orders just below support levels (e.g., $17.34) to manage downside risk and protect your capital from sudden market movements. |
| Sell at the right time | Plan to take profits near resistance points (e.g., around $18.28 or when targets are met) or if news signals a shift in Teva’s market prospects. |
The latest news about Teva Pharmaceuticals
Teva Pharmaceuticals has maintained nine consecutive quarters of revenue growth, affirming the effectiveness of its "Pivot to Growth" strategy. This sustainable expansion, confirmed most recently in Q1 2025, has been underpinned by robust sales across both generics and specialty products, demonstrating resilience in global markets, including Ireland, where Teva maintains a direct presence supporting local healthcare infrastructure. The company’s ongoing transformation under CEO Richard Francis, especially through operational refinements and a sharpened commercial focus, provides a constructive backdrop for continued recovery and positions Teva as a stable pharmaceutical partner for Irish healthcare providers.
Key innovative products, particularly AUSTEDO and UZEDY, have recorded performance exceeding expectations, driving strong momentum across developed markets. In 2024, AUSTEDO generated over $1.6 billion in revenues and UZEDY achieved $117 million—both surpassing internal targets—with AUSTEDO’s success reinforcing Teva’s footing in neurology and movement disorders, areas of significant therapeutic need in Ireland. This success story is relevant for the Irish market, as AUSTEDO is increasingly prescribed for Huntington’s disease and tardive dyskinesia, with reimbursement pathways aligning to HSE guidelines. The company’s strong specialty portfolio, coupled with a growing biosimilar pipeline, enhances access to affordable medicines for regional healthcare systems.
Teva has recently achieved a crucial regulatory milestone, securing US FDA Fast Track designation for TEV-53408 in celiac disease, alongside positive Phase 2B results for Duvakitug (Anti-TL1A). This advancement is significant for Irish analysts, as Ireland faces one of Europe’s highest celiac prevalence rates, and regulatory accelerations in the US are likely to influence the speed of European Medicines Agency (EMA) reviews. Such progress underscores Teva’s rising innovation credentials, potentially leading to earlier Irish availability of targeted therapies for autoimmune and gastrointestinal diseases, supporting unmet medical needs and broadening Teva’s relevance within the Irish market landscape.
Teva’s technical indicators, as of late May 2025, show a broadly neutral stance with positive bias, supported by buy signals on several key moving averages. Specifically, the 5-day, 50-day, 100-day, and 200-day moving averages all point to buy conditions, while the MACD remains positive. The company’s Relative Strength Index (RSI) hovers near 49, suggesting neither overbought nor oversold status, with the stochastic oscillator in the oversold zone. These signals, together with a consensus analyst target price of approximately $23.12 (+30% upside from current levels), provide a constructive technical and sentiment framework relevant for Irish institutional investors seeking entry points or portfolio allocation adjustments.
Teva continues to deepen its engagement with the Irish market through substantial generic and biosimilar product distribution, supporting the HSE’s cost-containment priorities and patient access objectives. Operating in Ireland via integrated supply chains and direct sales channels, Teva secures its position as one of the primary contributors to national medicine savings, with a particular emphasis on chronic disease therapies. Expansion in biosimilars—now 18 assets in the pipeline—aligns with ongoing shifts in Irish health policy toward sustainable access and budget predictability, bolstering Teva’s strategic presence and dimming long-term competitive risks.
FAQ
What is the latest dividend for Teva Pharmaceuticals stock?
Teva Pharmaceuticals does not currently pay a dividend to shareholders. The company suspended its dividend several years ago as part of a broader financial restructuring and has not indicated plans to resume payouts in the near term. Historically, Teva was a regular dividend payer but has focused recent cash flows on reducing debt and investing in its growing product pipeline.
What is the forecast for Teva Pharmaceuticals stock in 2025, 2026, and 2027?
Based on the latest share price of $17.53, forecasts indicate a value of $22.78 by the end of 2025, $26.30 by the end of 2026, and $35.06 by the end of 2027. These optimistic projections reflect Teva’s ongoing transformation, solid innovation pipeline, and strong presence in both specialty and generic medicines, supported by recent analyst upgrades and robust revenue outlook.
Should I sell my Teva Pharmaceuticals shares?
It may be worthwhile to hold Teva Pharmaceuticals shares given the current valuation and ongoing recovery. The company has demonstrated nine consecutive quarters of growth and is benefitting from innovation in its specialty drug and biosimilar segments. While debt remains a consideration, Teva’s global reach and successful strategic pivot enhance its mid- to long-term growth prospects, making continued holding potentially attractive for investors seeking exposure to the pharmaceutical sector’s momentum.
How are Teva Pharmaceuticals stock dividends and capital gains taxed in Ireland?
As an Irish resident, dividends from Teva Pharmaceuticals (a US-listed stock) are generally subject to US withholding tax, typically at 15% with correct forms, and are taxed as income in Ireland. Capital gains are taxed at Ireland’s standard rate for gains (currently 33%). Teva does not currently pay a dividend, but for any future distributions or gains, offset or credits for US withholding may be available depending on your tax position.
What is the latest dividend for Teva Pharmaceuticals stock?
Teva Pharmaceuticals does not currently pay a dividend to shareholders. The company suspended its dividend several years ago as part of a broader financial restructuring and has not indicated plans to resume payouts in the near term. Historically, Teva was a regular dividend payer but has focused recent cash flows on reducing debt and investing in its growing product pipeline.
What is the forecast for Teva Pharmaceuticals stock in 2025, 2026, and 2027?
Based on the latest share price of $17.53, forecasts indicate a value of $22.78 by the end of 2025, $26.30 by the end of 2026, and $35.06 by the end of 2027. These optimistic projections reflect Teva’s ongoing transformation, solid innovation pipeline, and strong presence in both specialty and generic medicines, supported by recent analyst upgrades and robust revenue outlook.
Should I sell my Teva Pharmaceuticals shares?
It may be worthwhile to hold Teva Pharmaceuticals shares given the current valuation and ongoing recovery. The company has demonstrated nine consecutive quarters of growth and is benefitting from innovation in its specialty drug and biosimilar segments. While debt remains a consideration, Teva’s global reach and successful strategic pivot enhance its mid- to long-term growth prospects, making continued holding potentially attractive for investors seeking exposure to the pharmaceutical sector’s momentum.
How are Teva Pharmaceuticals stock dividends and capital gains taxed in Ireland?
As an Irish resident, dividends from Teva Pharmaceuticals (a US-listed stock) are generally subject to US withholding tax, typically at 15% with correct forms, and are taxed as income in Ireland. Capital gains are taxed at Ireland’s standard rate for gains (currently 33%). Teva does not currently pay a dividend, but for any future distributions or gains, offset or credits for US withholding may be available depending on your tax position.
